MX2017005823A - Metodos para transduccion y procesamiento celular. - Google Patents
Metodos para transduccion y procesamiento celular.Info
- Publication number
- MX2017005823A MX2017005823A MX2017005823A MX2017005823A MX2017005823A MX 2017005823 A MX2017005823 A MX 2017005823A MX 2017005823 A MX2017005823 A MX 2017005823A MX 2017005823 A MX2017005823 A MX 2017005823A MX 2017005823 A MX2017005823 A MX 2017005823A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- transduction
- processing
- cells
- increased
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 7
- 230000026683 transduction Effects 0.000 title abstract 3
- 238000010361 transduction Methods 0.000 title abstract 3
- 241000700605 Viruses Species 0.000 abstract 1
- 238000011467 adoptive cell therapy Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000011534 incubation Methods 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000003672 processing method Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000013603 viral vector Substances 0.000 abstract 1
- 238000005406 washing Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B04—CENTRIFUGAL APPARATUS OR MACHINES FOR CARRYING-OUT PHYSICAL OR CHEMICAL PROCESSES
- B04B—CENTRIFUGES
- B04B7/00—Elements of centrifuges
- B04B7/08—Rotary bowls
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
Se proporcionan métodos, sistemas y kits para procesamiento celular, por ejemplo, para uso terapéutico, tal como para terapia celular adoptiva. Los métodos proporcionados incluyen métodos de transducción, en los cuales las células y virus se incuban bajo condiciones que dan por resultado la transducción de las células con un vector viral. La incubación en algunas modalidades se lleva a cabo en una cavidad interna de una cámara centrífuga generalmente rígida, tal como una cámara cilíndrica hecha de plástico duro, la cavidad de la cual puede tener un volumen variable. Los métodos incluyen otras etapas de procesamiento, que incluyen aquellos llevados a cabo en tal cámara, incluyendo el lavado, selección, aislamiento, cultivo y formulación. En particular, la descripción se relaciona a un método que proporciona ventajas sobre los métodos de procesamiento disponibles, tales como los métodos disponibles para procesamiento a gran escala. Tales ventajas incluyen, por ejemplo, costo reducido, optimización, eficacia incrementada, seguridad incrementada y reproductibilidad incrementada entre diferentes sujetos y condiciones.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462075801P | 2014-11-05 | 2014-11-05 | |
US201562129023P | 2015-03-05 | 2015-03-05 | |
PCT/US2015/059030 WO2016073602A2 (en) | 2014-11-05 | 2015-11-04 | Methods for transduction and cell processing |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017005823A true MX2017005823A (es) | 2017-08-02 |
Family
ID=54754736
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017005823A MX2017005823A (es) | 2014-11-05 | 2015-11-04 | Metodos para transduccion y procesamiento celular. |
MX2022000159A MX2022000159A (es) | 2014-11-05 | 2017-05-03 | Metodos para transduccion y procesamiento celular. |
MX2021001334A MX2021001334A (es) | 2014-11-05 | 2017-05-03 | Metodos para transduccion y procesamiento celular. |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022000159A MX2022000159A (es) | 2014-11-05 | 2017-05-03 | Metodos para transduccion y procesamiento celular. |
MX2021001334A MX2021001334A (es) | 2014-11-05 | 2017-05-03 | Metodos para transduccion y procesamiento celular. |
Country Status (27)
Country | Link |
---|---|
US (3) | US10428351B2 (es) |
EP (2) | EP3215601B1 (es) |
JP (3) | JP6740234B2 (es) |
KR (2) | KR102635942B1 (es) |
CN (2) | CN107109438B (es) |
AU (3) | AU2015343121B2 (es) |
BR (2) | BR122020002722B1 (es) |
CA (1) | CA2966538A1 (es) |
CY (1) | CY1123254T1 (es) |
DK (1) | DK3215601T3 (es) |
ES (1) | ES2805674T3 (es) |
HR (1) | HRP20201128T1 (es) |
HU (1) | HUE050264T2 (es) |
IL (2) | IL252126B (es) |
LT (1) | LT3215601T (es) |
MA (1) | MA40318A (es) |
MX (3) | MX2017005823A (es) |
MY (1) | MY186199A (es) |
NZ (2) | NZ769595A (es) |
PH (1) | PH12017500824A1 (es) |
PL (1) | PL3215601T3 (es) |
PT (1) | PT3215601T (es) |
RS (1) | RS60685B1 (es) |
SG (2) | SG11201703656PA (es) |
SI (1) | SI3215601T1 (es) |
TW (3) | TWI787903B (es) |
WO (1) | WO2016073602A2 (es) |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2948544A4 (en) | 2013-01-28 | 2016-08-03 | St Jude Childrens Res Hospital | CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES |
US10428305B2 (en) | 2014-05-15 | 2019-10-01 | National University Of Singapore | Modified natural killer cells that express IL15 and uses thereof |
MX2017005106A (es) | 2014-10-20 | 2017-07-05 | Juno Therapeutics Inc | Metodos y composiciones para dosificacion en terapia celular adoptiva. |
TWI787903B (zh) | 2014-11-05 | 2022-12-21 | 美商奇諾治療有限公司 | 用於轉導作用及細胞處理之方法 |
CN107106744B (zh) | 2014-12-19 | 2020-12-01 | 生物安全股份有限公司 | 生物流体的顺序处理 |
MA41346A (fr) | 2015-01-12 | 2017-11-21 | Juno Therapeutics Inc | Eléments régulateurs post-transcriptionnels d'hépatite modifiée |
PL3298033T5 (pl) | 2015-05-18 | 2023-10-30 | TCR2 Therapeutics Inc. | Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych |
RU2021134624A (ru) | 2015-10-22 | 2022-03-15 | Джуно Терапьютикс Гмбх | Способы, наборы, средства и устройства для трансдукции |
CN109196357A (zh) * | 2016-03-07 | 2019-01-11 | 日立化学高级疗法解决方案有限责任公司 | 用于标记和选择活细胞的封闭系统 |
MA43759A (fr) | 2016-03-16 | 2018-11-28 | Jason Connor | Procédés de conception adaptative d'un régime de traitement et traitements associés |
JP7062640B2 (ja) | 2016-07-29 | 2022-05-06 | ジュノー セラピューティクス インコーポレイテッド | 抗cd19抗体に対する抗イディオタイプ抗体 |
JP7109789B2 (ja) | 2016-08-02 | 2022-08-01 | ティーシーアール2 セラピューティクス インク. | 融合タンパク質を使用したtcrの再プログラム化のための組成物及び方法 |
KR20190045321A (ko) | 2016-09-12 | 2019-05-02 | 주노 쎄러퓨티크스 인코퍼레이티드 | 관류 생물 반응기 백 조립체 |
IL292551B2 (en) | 2016-10-07 | 2023-10-01 | Tcr2 Therapeutics Inc | Preparations and methods for reprogramming T-cell receptors using fusion proteins |
US11851491B2 (en) | 2016-11-22 | 2023-12-26 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
US20200095547A1 (en) * | 2016-12-02 | 2020-03-26 | Darya ALIZADEH | Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors |
BR112019011207A2 (pt) * | 2016-12-05 | 2019-10-08 | Juno Therapeutics Inc | produção de células modificadas para terapia celular adotiva |
EP4353818A2 (en) | 2017-02-27 | 2024-04-17 | Juno Therapeutics, Inc. | Compositions, articles of manufacture and methods related to dosing in cell therapy |
EP3595440A2 (en) | 2017-03-14 | 2020-01-22 | Juno Therapeutics, Inc. | Methods for cryogenic storage |
CA3056591A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
EP3427052A4 (en) * | 2017-03-27 | 2019-12-04 | Hitachi Chemical Advanced Therapeutics Solutions, LLC | CLOSED SYSTEM FOR MARKING AND SELECTING LIVING CELLS |
CA3056439A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy |
AU2018275894A1 (en) * | 2017-06-02 | 2019-12-12 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
WO2019027850A1 (en) | 2017-07-29 | 2019-02-07 | Juno Therapeutics, Inc. | CELL EXPANSION REAGENTS EXPRESSING RECOMBINANT RECEPTORS |
AU2018324180A1 (en) | 2017-09-01 | 2020-03-19 | Lonza Cologne Gmbh | End-to-end cell therapy automation |
WO2019051335A1 (en) | 2017-09-07 | 2019-03-14 | Juno Therapeutics, Inc. | METHODS OF IDENTIFYING CELLULAR CHARACTERISTICS RELATED TO RESPONSES ASSOCIATED WITH CELL THERAPY |
BR112020008340A2 (pt) | 2017-11-01 | 2020-11-17 | Juno Therapeutics Inc | processo para gerar composições terapêuticas de células modificadas |
US20210254000A1 (en) | 2017-11-01 | 2021-08-19 | Juno Therapeutics, Inc. | Process for producing a t cell composition |
KR20200095487A (ko) | 2017-11-10 | 2020-08-10 | 주노 쎄러퓨티크스 인코퍼레이티드 | 폐쇄-시스템 극저온 용기 |
WO2019113556A1 (en) | 2017-12-08 | 2019-06-13 | Juno Therapeutics, Inc. | Serum-free media formulation for culturing cells and methods of use thereof |
US20210128616A1 (en) | 2017-12-08 | 2021-05-06 | Juno Therapeutics, Inc. | Phenotypic markers for cell therapy and related methods |
SG11202005272SA (en) | 2017-12-08 | 2020-07-29 | Juno Therapeutics Inc | Process for producing a composition of engineered t cells |
MA51792A (fr) | 2018-02-09 | 2020-12-16 | Immatics Us Inc | Procédés de fabrication de lymphocytes t |
JP2021533746A (ja) | 2018-08-09 | 2021-12-09 | ジュノー セラピューティクス インコーポレイテッド | 操作された細胞およびその組成物を生成するための方法 |
AU2019316647A1 (en) | 2018-08-09 | 2021-02-25 | Juno Therapeutics, Inc. | Methods for assessing integrated nucleic acids |
CA3111789A1 (en) | 2018-09-11 | 2020-03-19 | Juno Therapeutics, Inc. | Methods for mass spectrometry analysis of engineered cell compositions |
JP2022512872A (ja) | 2018-10-31 | 2022-02-07 | ジュノ セラピューティクス ゲーエムベーハー | 細胞の選択および刺激のための方法ならびにそのための装置 |
EP3873943A2 (en) | 2018-11-01 | 2021-09-08 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
JP2022008735A (ja) * | 2018-11-06 | 2022-01-14 | テルモ株式会社 | 細胞製造システム、細胞製造方法、医療装置及び医療デバイス |
CA3117720A1 (en) | 2018-11-06 | 2020-05-14 | Juno Therapeutics, Inc. | Process for producing genetically engineered t cells |
SG11202105084VA (en) | 2018-11-16 | 2021-06-29 | Juno Therapeutics Inc | Methods of dosing engineered t cells for the treatment of b cell malignancies |
WO2020113188A2 (en) | 2018-11-30 | 2020-06-04 | Juno Therapeutics, Inc. | Methods for dosing and treatment of b cell malignancies in adoptive cell therapy |
JP2022513685A (ja) | 2018-11-30 | 2022-02-09 | ジュノー セラピューティクス インコーポレイテッド | 養子細胞療法を用いた処置のための方法 |
JP2022519154A (ja) * | 2018-12-07 | 2022-03-22 | グレイセル・バイオテクノロジーズ(シャンハイ)カンパニー・リミテッド | 免疫療法のための組成物および方法 |
SG11202106384YA (en) | 2018-12-21 | 2021-07-29 | Octane Biotech Inc | Carousel for modular biologic production units |
JP2022514761A (ja) | 2018-12-21 | 2022-02-15 | ロンザ ウォーカーズヴィル,インコーポレーテッド | ウイルスベクターの自動産生方法 |
CN113498432A (zh) | 2019-02-08 | 2021-10-12 | 隆萨沃克斯维尔股份有限公司 | 用于自动化生物反应器的细胞浓缩方法和装置 |
WO2020180882A1 (en) | 2019-03-05 | 2020-09-10 | Nkarta, Inc. | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy |
WO2020196412A1 (ja) * | 2019-03-26 | 2020-10-01 | テルモ株式会社 | 遠心部材及び洗浄方法 |
EP3980530A1 (en) | 2019-06-07 | 2022-04-13 | Juno Therapeutics, Inc. | Automated t cell culture |
WO2020250927A1 (ja) * | 2019-06-10 | 2020-12-17 | アイ ピース, インコーポレイテッド | 赤血球除去装置、単核球回収器、細胞培養装置、細胞培養システム、細胞培養方法、及び単核球の回収方法 |
SG11202113356XA (en) | 2019-06-12 | 2021-12-30 | Juno Therapeutics Inc | Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein |
KR20220066892A (ko) | 2019-08-22 | 2022-05-24 | 주노 쎄러퓨티크스 인코퍼레이티드 | T 세포 요법 및 제스트 동족체 2의 인핸서 (ezh2) 억제제의 병용 요법 및 관련 방법 |
US20220392613A1 (en) | 2019-08-30 | 2022-12-08 | Juno Therapeutics, Inc. | Machine learning methods for classifying cells |
AU2020377043A1 (en) | 2019-10-30 | 2022-06-02 | Juno Therapeutics Gmbh | Cell selection and/or stimulation devices and methods of use |
JP2022554348A (ja) | 2019-11-05 | 2022-12-28 | ジュノー セラピューティクス インコーポレイテッド | 治療用t細胞組成物の属性を決定する方法 |
KR20220132527A (ko) | 2019-12-06 | 2022-09-30 | 주노 쎄러퓨티크스 인코퍼레이티드 | B 세포 악성 종양을 치료하기 위한 세포 요법과 연관된 독성 및 반응과 관련된 방법 |
EP4069742A1 (en) | 2019-12-06 | 2022-10-12 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods |
BR112022010627A2 (pt) | 2019-12-06 | 2022-08-16 | Juno Therapeutics Inc | Anticorpos anti-idiotípicos para domínios de ligação alvejados por bcma e composições e métodos relacionados |
WO2021148019A1 (zh) * | 2020-01-22 | 2021-07-29 | 科济生物医药(上海)有限公司 | 病毒载体转导细胞的方法 |
WO2021151008A1 (en) | 2020-01-24 | 2021-07-29 | Juno Therapuetics, Inc. | Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in adoptive cell therapy |
JP2023512209A (ja) | 2020-01-28 | 2023-03-24 | ジュノー セラピューティクス インコーポレイテッド | T細胞形質導入のための方法 |
AU2021217829A1 (en) * | 2020-02-06 | 2022-08-18 | Cutiss Ag | Cell isolation device and method |
JP2023519099A (ja) | 2020-02-12 | 2023-05-10 | ジュノー セラピューティクス インコーポレイテッド | Bcma指向性キメラ抗原受容体t細胞組成物ならびにその方法および使用 |
KR20220152220A (ko) | 2020-02-12 | 2022-11-15 | 주노 쎄러퓨티크스 인코퍼레이티드 | Cd19-지시된 키메라 항원 수용체 t 세포 조성물 및 이의 방법 및 용도 |
EP4127140A1 (en) * | 2020-04-03 | 2023-02-08 | Millennium Pharmaceuticals, Inc. | Enhanced viral transduction efficiency |
AU2021251265A1 (en) | 2020-04-10 | 2022-11-03 | Juno Therapeutics, Inc. | Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting B-cell maturation antigen |
WO2021231657A1 (en) | 2020-05-13 | 2021-11-18 | Juno Therapeutics, Inc. | Methods of identifying features associated with clinical response and uses thereof |
WO2021231661A2 (en) | 2020-05-13 | 2021-11-18 | Juno Therapeutics, Inc. | Process for producing donor-batched cells expressing a recombinant receptor |
KR20230095918A (ko) | 2020-08-05 | 2023-06-29 | 주노 쎄러퓨티크스 인코퍼레이티드 | Ror1-표적 결합 도메인에 대한 항이디오타입 항체 및 관련 조성물 및 방법 |
WO2022133030A1 (en) | 2020-12-16 | 2022-06-23 | Juno Therapeutics, Inc. | Combination therapy of a cell therapy and a bcl2 inhibitor |
JP2024507199A (ja) | 2021-02-20 | 2024-02-16 | カイト ファーマ インコーポレイテッド | 免疫療法を選択するための遺伝子マーカー |
WO2022204071A1 (en) | 2021-03-22 | 2022-09-29 | Juno Therapeutics, Inc. | Method to assess potency of viral vector particles |
CA3210581A1 (en) | 2021-03-22 | 2022-09-29 | Neil HAIG | Methods of determining potency of a therapeutic cell composition |
KR20240005700A (ko) | 2021-03-29 | 2024-01-12 | 주노 쎄러퓨티크스 인코퍼레이티드 | 체크포인트 억제제 요법 및 car t 세포 요법의 조합을 사용한 투여 및 치료 방법 |
CN117916256A (zh) | 2021-05-06 | 2024-04-19 | 朱诺治疗学有限公司 | 用于刺激和转导t细胞的方法 |
US20220378830A1 (en) | 2021-05-14 | 2022-12-01 | Kite Pharma, Inc. | Chimeric antigen receptor t cell therapy |
WO2023159001A1 (en) | 2022-02-15 | 2023-08-24 | Kite Pharma, Inc. | Predicting adverse events from immunotherapy |
WO2023225569A1 (en) | 2022-05-17 | 2023-11-23 | Umoja Biopharma, Inc. | Manufacturing viral particles |
WO2023230548A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Method for predicting response to a t cell therapy |
WO2023230581A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Methods of manufacturing t cell therapies |
WO2023250400A1 (en) | 2022-06-22 | 2023-12-28 | Juno Therapeutics, Inc. | Treatment methods for second line therapy of cd19-targeted car t cells |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4163519A (en) | 1977-11-01 | 1979-08-07 | Union Carbide Corporation | Compensating rotor |
US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
IN165717B (es) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
SE454413B (sv) | 1986-09-12 | 1988-05-02 | Alfa Laval Separation Ab | Centrifugalseparator med en rotor, vari ett bojligt organ strecker sig ett stycke lengs rotorns omkrets |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
DE68919715T2 (de) | 1988-12-28 | 1995-04-06 | Stefan Miltenyi | Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien. |
US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
ATE159548T1 (de) | 1990-11-13 | 1997-11-15 | Immunex Corp | Bifunktionelle wählbare fusionsgene |
US5911983A (en) * | 1992-06-26 | 1999-06-15 | University Of Pittsburgh | Gene therapy for Gaucher disease using retroviral vectors |
WO1994028143A1 (en) | 1993-05-21 | 1994-12-08 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
US5437998A (en) * | 1993-09-09 | 1995-08-01 | Synthecon, Inc. | Gas permeable bioreactor and method of use |
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
JP2000501614A (ja) | 1995-12-15 | 2000-02-15 | システミックス,インコーポレイテッド | 高形質導入効率を有するレトロウイルスベクター上清を得るための方法 |
DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
US6451995B1 (en) | 1996-03-20 | 2002-09-17 | Sloan-Kettering Institute For Cancer Research | Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods |
WO1997015399A1 (en) * | 1996-04-24 | 1997-05-01 | Claude Fell | Cell separation system for biological fluids like blood |
ATE452982T1 (de) * | 1998-07-10 | 2010-01-15 | Univ Paris Curie | Verfahren zur verabreichng von nukleinsäuren in zellen in vitro oder ex vivo |
WO2000014257A1 (en) | 1998-09-04 | 2000-03-16 | Sloan-Kettering Institute For Cancer Research | Fusion receptors specific for prostate-specific membrane antigen and uses thereof |
AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
ES2224726T3 (es) | 1998-12-24 | 2005-03-01 | Biosafe S.A. | Sistema de separacion sanguinea indicado en particular para la concentracion de celulas madre hematopoyeticas. |
WO2001094944A2 (en) | 2000-06-02 | 2001-12-13 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
WO2002077029A2 (en) | 2000-11-07 | 2002-10-03 | City Of Hope | Cd19-specific redirected immune cells |
US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
DE10136375A1 (de) | 2001-07-26 | 2003-02-13 | Cellgenix Technologie Transfer | Verfahren zur Anreicherung von Zellen |
US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
US7001513B2 (en) | 2003-08-06 | 2006-02-21 | Nuvue Technologies, Inc. | Automated processing of a biological component |
US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
DK1893253T3 (da) | 2005-03-23 | 2010-08-16 | Biosafe Sa | Integreret system til opsamling, forarbejdning og transplantation af celledelmængder, omfattende voksenstamceller til regenerativ medicin |
JP5453629B2 (ja) * | 2006-08-23 | 2014-03-26 | タカラバイオ株式会社 | 遠心用袋状容器を使用した遺伝子導入方法 |
ES2529166T3 (es) | 2007-03-30 | 2015-02-17 | Memorial Sloan-Kettering Cancer Center | Expresión constitutiva de ligandos coestimuladores en linfocitos T transferidos de forma adoptiva |
ES2374863T3 (es) | 2007-12-07 | 2012-02-22 | Miltenyi Biotec Gmbh | Centrífuga para separar una muestra en por lo menos dos componentes. |
US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
EP2310486B1 (en) * | 2008-07-16 | 2017-01-04 | kSep Systems, LLC | Methods and systems for manipulating particles using a fluidized bed |
PL2496698T3 (pl) | 2009-11-03 | 2019-07-31 | City Of Hope | Skrócony receptor naskórkowego czynnika wzrostu (EGFRt) do selekcji transdukowanych komórek T |
US8747289B2 (en) | 2010-03-18 | 2014-06-10 | Syngen Inc. | System for purifying certain cell populations in blood or bone marrow by depleting others |
SE535275C2 (sv) | 2010-03-31 | 2012-06-12 | Alfa Laval Corp Ab | Centrifugalseparator och rotor |
JP5793567B2 (ja) * | 2010-07-15 | 2015-10-14 | テルモ ビーシーティー、インコーポレーテッド | 生体液用の遠心分離装置において回転時間を最適化するための方法 |
CN106220739A (zh) | 2010-12-09 | 2016-12-14 | 宾夕法尼亚大学董事会 | 嵌合抗原受体‑修饰的t细胞治疗癌症的用途 |
BR112013018311A2 (pt) * | 2011-01-18 | 2017-03-21 | Univ Pennsylvania | sequência de ácido nucleico isolada, receptor de antígeno quimérico isolado, célula t geneticamente modificada, vetor, e, uso de uma célula t geneticamente modificada. |
KR101976882B1 (ko) | 2011-03-23 | 2019-05-09 | 프레드 헛친슨 켄서 리서치 센터 | 세포 면역요법용 방법 및 조성물 |
US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
US9969966B2 (en) * | 2011-05-30 | 2018-05-15 | Atech Partners Limited | Bioreactor system for continuous cell cultivation |
CN102329776B (zh) * | 2011-07-20 | 2013-02-27 | 华中农业大学 | 一种表达Nectin-1基因胞外区片段的PK-15细胞系及其构建方法 |
JP6053688B2 (ja) * | 2011-10-07 | 2016-12-27 | 国立大学法人三重大学 | キメラ抗原受容体 |
CN107880101B (zh) | 2011-11-11 | 2021-12-21 | 弗雷德哈钦森癌症研究中心 | 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法 |
EP2594632A1 (en) * | 2011-11-18 | 2013-05-22 | Miltenyi Biotec GmbH | Method and device for cell modification |
AU2013221672B2 (en) | 2012-02-13 | 2017-11-09 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
CN106940268B (zh) * | 2012-02-23 | 2021-09-21 | 朱诺治疗有限公司 | 细胞和其它复杂生物材料的色谱分离 |
EP3763820B1 (en) | 2012-02-29 | 2021-12-22 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Retroviral transduction using poloxamers |
IN2014DN06925A (es) | 2012-03-13 | 2015-04-10 | Emd Millipore Corp | |
NZ702108A (en) | 2012-05-03 | 2016-09-30 | Hutchinson Fred Cancer Res | Enhanced affinity t cell receptors and methods for making the same |
EP2698208A1 (de) | 2012-08-14 | 2014-02-19 | Fresenius Kabi Deutschland GmbH | Zentrifugenvorrichtung und Verfahren zum Betreiben einer Zentrifugenvorrichtung |
IL293944A (en) | 2012-08-20 | 2022-08-01 | Hutchinson Fred Cancer Res | Method and preparations for cellular immunotherapy |
KR102198058B1 (ko) | 2012-10-02 | 2021-01-06 | 메모리얼 슬로안 케터링 캔서 센터 | 면역치료용 조성물 및 방법 |
US9405601B2 (en) | 2012-12-20 | 2016-08-02 | Mitsubishi Electric Corporation | In-vehicle apparatus and program |
UY35468A (es) * | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
EP3789487A1 (en) * | 2013-04-03 | 2021-03-10 | Memorial Sloan Kettering Cancer Center | Effective generation of tumor-targeted t-cells derived from pluripotent stem cells |
US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
RU2733652C2 (ru) | 2013-10-31 | 2020-10-06 | Фред Хатчинсон Кэнсер Рисерч Сентер | МОДИФИЦИРОВАННЫЕ ГЕМОПОЭТИЧЕСКИЕ СТВОЛОВЫЕ КЛЕТКИ/КЛЕТКИ-ПРЕДШЕСТВЕННИКИ И Не-Т ЭФФЕКТОРНЫЕ КЛЕТКИ, И ИХ ПРИМЕНЕНИЕ |
IL292038A (en) | 2014-04-23 | 2022-06-01 | Juno Therapeutics Inc | Methods for enriching and producing immune cell populations for stress treatment |
ES2708584T3 (es) | 2014-04-24 | 2019-04-10 | Miltenyi Biotec Gmbh | Método para la generación automatizada de células T modificadas genéticamente |
TWI787903B (zh) | 2014-11-05 | 2022-12-21 | 美商奇諾治療有限公司 | 用於轉導作用及細胞處理之方法 |
MA41346A (fr) | 2015-01-12 | 2017-11-21 | Juno Therapeutics Inc | Eléments régulateurs post-transcriptionnels d'hépatite modifiée |
-
2015
- 2015-11-04 TW TW110125506A patent/TWI787903B/zh active
- 2015-11-04 SG SG11201703656PA patent/SG11201703656PA/en unknown
- 2015-11-04 ES ES15802231T patent/ES2805674T3/es active Active
- 2015-11-04 MX MX2017005823A patent/MX2017005823A/es unknown
- 2015-11-04 PT PT158022319T patent/PT3215601T/pt unknown
- 2015-11-04 JP JP2017543300A patent/JP6740234B2/ja active Active
- 2015-11-04 CN CN201580072404.4A patent/CN107109438B/zh active Active
- 2015-11-04 SI SI201531268T patent/SI3215601T1/sl unknown
- 2015-11-04 IL IL252126A patent/IL252126B/en unknown
- 2015-11-04 EP EP15802231.9A patent/EP3215601B1/en active Active
- 2015-11-04 HU HUE15802231A patent/HUE050264T2/hu unknown
- 2015-11-04 LT LTEP15802231.9T patent/LT3215601T/lt unknown
- 2015-11-04 US US14/932,660 patent/US10428351B2/en active Active
- 2015-11-04 KR KR1020177015404A patent/KR102635942B1/ko active IP Right Grant
- 2015-11-04 NZ NZ769595A patent/NZ769595A/en unknown
- 2015-11-04 IL IL292450A patent/IL292450A/en unknown
- 2015-11-04 TW TW104136385A patent/TWI735418B/zh active
- 2015-11-04 MY MYPI2017000656A patent/MY186199A/en unknown
- 2015-11-04 WO PCT/US2015/059030 patent/WO2016073602A2/en active Application Filing
- 2015-11-04 AU AU2015343121A patent/AU2015343121B2/en active Active
- 2015-11-04 EP EP20176047.7A patent/EP3757206B1/en active Active
- 2015-11-04 NZ NZ769598A patent/NZ769598A/en unknown
- 2015-11-04 CN CN202111026157.8A patent/CN113736828A/zh active Pending
- 2015-11-04 CA CA2966538A patent/CA2966538A1/en not_active Abandoned
- 2015-11-04 BR BR122020002722-3A patent/BR122020002722B1/pt not_active IP Right Cessation
- 2015-11-04 BR BR112017009220-4A patent/BR112017009220B1/pt active IP Right Grant
- 2015-11-04 TW TW111132488A patent/TW202315948A/zh unknown
- 2015-11-04 SG SG10202002324SA patent/SG10202002324SA/en unknown
- 2015-11-04 KR KR1020247004412A patent/KR20240023204A/ko active Application Filing
- 2015-11-04 MA MA040318A patent/MA40318A/fr unknown
- 2015-11-04 DK DK15802231.9T patent/DK3215601T3/da active
- 2015-11-04 PL PL15802231T patent/PL3215601T3/pl unknown
- 2015-11-04 RS RS20200887A patent/RS60685B1/sr unknown
-
2017
- 2017-05-03 MX MX2022000159A patent/MX2022000159A/es unknown
- 2017-05-03 MX MX2021001334A patent/MX2021001334A/es unknown
- 2017-05-04 PH PH12017500824A patent/PH12017500824A1/en unknown
-
2019
- 2019-08-14 US US16/541,083 patent/US11802295B2/en active Active
-
2020
- 2020-07-17 HR HRP20201128TT patent/HRP20201128T1/hr unknown
- 2020-07-22 JP JP2020124934A patent/JP7202332B2/ja active Active
- 2020-08-13 CY CY20201100763T patent/CY1123254T1/el unknown
- 2020-09-14 AU AU2020233623A patent/AU2020233623B2/en active Active
-
2022
- 2022-11-03 AU AU2022263539A patent/AU2022263539A1/en active Pending
- 2022-12-23 JP JP2022206247A patent/JP2023024691A/ja active Pending
-
2023
- 2023-09-21 US US18/371,302 patent/US20240011051A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017500824A1 (en) | Methods for transduction and cell processing | |
AU2021209195B2 (en) | Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy | |
MX2022000221A (es) | Viriones de virus adenoasociados con capside variante y metodos para su uso. | |
BR112020003925A2 (pt) | Produtos alimentícios comestíveis e projetos de biorreator | |
EP4219696A3 (en) | Oncolytic virus strain | |
MX2019010735A (es) | Sistemas y metodos para la produccion dirigida de una proteina terapeutica dentro de una celula objetivo. | |
MX2018012880A (es) | Metodos para proporcionar arn de hebra sencilla. | |
WO2017044857A3 (en) | Methods and compositions for the treatment of glaucoma | |
WO2016090178A3 (en) | Processes for producing exosomes in reduced oxygen culture conditions | |
SG10201902574RA (en) | Adeno-associated virus vector variants for high efficiency genome editing and methods thereof | |
MX2021000435A (es) | Moleculas biespecificas que son inmunorreactivas con celulas efectoras inmunes que expresan un receptor activador y un antigeno expresado por una celula infectada por un virus y usos de las mismas. | |
SG10201900323SA (en) | Method for inducing t cells for cell-based immunotherapy from pluripotent stem cells | |
MX370018B (es) | Metodos mejorados para la elaboracion de terapias celulares adoptivas. | |
BR112016016916A2 (pt) | método de tratamento de angiodema hereditário (hae) | |
GB2548740A (en) | Methods for generation of podocytes from pluripotent stem cells and cells produced by the same | |
EP4234032A3 (en) | Induction medium and methods for stem cell culture and therapy | |
SG10201901559SA (en) | Retinal ganglion cells and progenitors thereof | |
WO2014026110A3 (en) | Compounds for improved viral transduction | |
EP4275746A3 (en) | Extracellular vesicles derived from osteoblastic lineage cells for therapeutic and diagnostic use | |
MX2018011980A (es) | 3-epimerasa y polinucleotido que la codifica. | |
AU2018337668A1 (en) | Improved supraparticles | |
AU2016250096A8 (en) | Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features | |
EA202190474A1 (ru) | Терапия на основе микро-рнк, направленная против lcp-1-позитивных раковых опухолей | |
BR112016024635A2 (pt) | meios de crescimento microbiológico e métodos de uso do mesmo | |
BR112017001696A2 (pt) | composições de célula-tronco e métodos de produção de células-tronco para aplicações terapêuticas |